Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03963895
Recruitment Status : Recruiting
First Posted : May 27, 2019
Last Update Posted : July 30, 2019
Sponsor:
Collaborator:
Celerion
Information provided by (Responsible Party):
Aronora, Inc.

Brief Summary:
This study evaluates the safety and efficacy of AB002 (E-WE thrombin) in patients with end stage renal disease on chronic hemodialysis. Two dose levels will be evaluated in two cohorts. Within each cohort the patients will be randomized to receive either AB002 (E-WE thrombin) or placebo (at a ratio of 2:1 active: placebo).

Condition or disease Intervention/treatment Phase
End Stage Renal Disease Thrombosis Drug: AB002 Drug: placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of a Single Dose of E-WE Thrombin, Administered During a Regular Hemodialysis Procedure, in Patients With End-Stage Renal Disease on Chronic Hemodialysis
Actual Study Start Date : July 10, 2019
Estimated Primary Completion Date : October 2020
Estimated Study Completion Date : October 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: AB002 (E-WE-thrombin) Drug: AB002
AB002 (E-WE thrombin) specified dose on specified day administered as a single intravenous infusion
Other Name: E-WE thrombin

Placebo Comparator: placebo Drug: placebo
placebo specified dose on specified day administered as a single intravenous injection




Primary Outcome Measures :
  1. The number of subjects with treatment-related adverse events (TEAEs) will be summarized using frequency counts (safety and tolerability) [ Time Frame: 22 days ]
    TEAEs will be determined by physical examination that will include assessment of skin, head, ears, eyes, nose, throat, respiratory system, cardiovascular system, gastrointestinal system, neurological condition, blood and lymphatic systems, and the musculoskeletal system.

  2. The number of TEAEs will be summarized using frequency counts (safety and tolerability). [ Time Frame: 22 days ]
    TEAEs will be determined by physical examination that will include assessment of skin, head, ears, eyes, nose, throat, respiratory system, cardiovascular system, gastrointestinal system, neurological condition, blood and lymphatic systems, and the musculoskeletal system.

  3. Incidence of bleeding at the hemodialysis (HD) vascular access site (safety and tolerability) [ Time Frame: 22 days ]
    The number of patients with clinically relevant and non-major bleeding events from the vascular access site.

  4. The number of subjects with abnormal electrocardiogram that is related to treatment will be summarized using frequency counts (safety and tolerability). [ Time Frame: 22 days ]
    12-lead electrocardiogram measurement

  5. The number of subjects that develop antibodies to endogenous thrombin will be summarized using frequency counts (safety and tolerability). [ Time Frame: 22 days ]
    Immunogenicity measured by the presence of serum anti-thrombin antibodies

  6. The number of subjects with clinically significant changes in body temperature in relation to treatment will be assessed. [ Time Frame: 22 days ]
    Body temperature will be measured in degrees Celsius.

  7. The number of subjects with clinically significant changes in respiratory rate and relation to treatment will be assessed. [ Time Frame: 22 days ]
    Respiratory rate will be measured in breaths per minute.

  8. The number of subjects with clinically significant changes in blood pressure (systolic and diastolic) and relation to treatment will be assessed. [ Time Frame: 22 days ]
    Systolic and diastolic blood pressure will be measured in mmHg

  9. The number of subjects with clinically significant changes in heart rate and relation to treatment will be assessed. [ Time Frame: 22 days ]
    Heart rate will be measured in beats per minute.

  10. The number of subjects with clinically significant changes in activated partial thromboplastin time (aPTT) and relation to treatment will be assessed as part of a standard coagulation panel. [ Time Frame: 22 days ]
    Plasma aPTT will be measured in seconds.

  11. The number of subjects with clinically significant changes in prothrombin time and relation to treatment will be assessed as part of a standard coagulation panel. [ Time Frame: 22 days ]
    Prothrombin time will be measured in seconds.

  12. The number of subjects with clinically significant changes in plasma fibrinogen and relation to treatment will be assessed as part of a standard coagulation panel. [ Time Frame: 22 days ]
    Plasma fibrinogen will be measured in mg/dL

  13. The number of subjects with clinically significant changes in thrombin time and relation to treatment will be assessed as part of a standard coagulation panel. [ Time Frame: 22 days ]
    Thrombin time will be measured in seconds

  14. The number of subjects with clinically significant changes in bilirubin (total and direct) levels and relation to treatment will be assessed as part of a standard serum chemistry panel. [ Time Frame: 22 days ]
    Bilirubin (total and direct) levels in the blood will be measured in mg/dL.

  15. The number of subjects with clinically significant changes in alkaline phosphatase levels and relation to treatment will be assessed as part of a standard serum chemistry panel. [ Time Frame: 22 days ]
    Alkaline phosphatase levels in the blood will be measured in U/L.

  16. The number of subjects with clinically significant changes in aspartate aminotransferase (AST) levels and relation to treatment will be assessed as part of a standard serum chemistry panel. [ Time Frame: 22 days ]
    AST levels in the blood will be measured in U/L.

  17. The number of subjects with clinically significant changes in alanine aminotransferase (ALT) levels and relation to treatment will be assessed as part of a standard serum chemistry panel. [ Time Frame: 22 days ]
    ALT levels in the blood will be measured in U/L.

  18. The number of subjects with clinically significant changes in lactate dehydrogenase (LDH) levels and relation to treatment will be assessed as part of a standard serum chemistry panel. [ Time Frame: 22 days ]
    LDH levels in the blood will be measured in U/L.

  19. The number of subjects with clinically significant changes in albumin levels and relation to treatment will be assessed as part of a standard serum chemistry panel. [ Time Frame: 22 days ]
    Albumin levels in the blood will be measured in g/dL.

  20. The number of subjects with clinically significant changes in sodium levels and relation to treatment will be assessed as part of a standard serum chemistry panel. [ Time Frame: 22 days ]
    Sodium levels will be measured in mEq/L.

  21. The number of subjects with clinically significant changes in potassium levels and relation to treatment will be assessed as part of a standard serum chemistry panel. [ Time Frame: 22 days ]
    Potassium levels will be measured in mEq/L.

  22. The number of subjects with clinically significant changes in chloride levels and relation to treatment will be assessed as part of a standard serum chemistry panel. [ Time Frame: 22 days ]
    Chloride levels will be measured in mEq/L.

  23. The number of subjects with clinically significant changes in glucose levels and relation to treatment will be assessed as part of a standard serum chemistry panel. [ Time Frame: 22 days ]
    Blood glucose levels will be measured in mg/dL.

  24. The number of subjects with clinically significant changes in creatinine levels and relation to treatment will be assessed as part of a standard serum chemistry panel. [ Time Frame: 22 days ]
    Creatinine levels will be measured in mg/dL.

  25. The number of subjects with clinically significant changes in hemoglobin levels and relation to treatment will be assessed as part of a standard hematology panel. [ Time Frame: 22 days ]
    Hemoglobin levels will be measured in g/dL.

  26. The number of subjects with clinically significant changes in hematocrit levels and relation to treatment will be assessed as part of a standard hematology panel. [ Time Frame: 22 days ]
    Hematocrit levels will be measured in %.

  27. The number of subjects with clinically significant changes in total leukocyte counts and relation to treatment will be assessed as part of a standard hematology panel. [ Time Frame: 22 days ]
    Total leukocyte counts will be measured in 10˄3/uL.

  28. The number of subjects with clinically significant changes in differential leukocyte counts and relation to treatment will be assessed as part of a standard hematology panel. [ Time Frame: 22 days ]
    Differential leukocyte counts will be measured in %.

  29. The number of subjects with clinically significant changes in red blood cell count and relation to treatment will be assessed as part of a standard hematology panel. [ Time Frame: 22 days ]
    Red blood cell count will be measured in 10˄6/uL.

  30. The number of subjects with clinically significant changes in platelet count and relation to treatment will be assessed as part of a standard hematology panel. [ Time Frame: 22 days ]
    Platelet count will be measured in 10˄3/uL.

  31. The number of subjects with clinically significant changes in urine pH and relation to treatment will be assessed as part of a standard urinalysis panel (unless patient is anuric). [ Time Frame: 22 days ]
    pH of the urine will be measured.

  32. The number of subjects with clinically significant changes in urine specific gravity and relation to treatment will be assessed as part of a standard urinalysis panel (unless patient is anuric). [ Time Frame: 22 days ]
    Specific gravity of the urine will be evaluated.

  33. The number of subjects with clinically significant changes in urine protein levels and relation to treatment will be assessed as part of a standard urinalysis panel (unless patient is anuric). [ Time Frame: 22 days ]
    Protein levels in the urine will be evaluated.

  34. The number of subjects with clinically significant changes in urine glucose levels and relation to treatment will be assessed as part of a standard urinalysis panel (unless patient is anuric). [ Time Frame: 22 days ]
    Glucose levels in the urine will be evaluated.

  35. The number of subjects with clinically significant changes in urine ketone levels and relation to treatment will be assessed as part of a standard urinalysis panel (unless patient is anuric). [ Time Frame: 22 days ]
    Ketone levels in the urine will be evaluated.

  36. The number of subjects with clinically significant changes in urine bilirubin levels and relation to treatment will be assessed as part of a standard urinalysis panel (unless patient is anuric). [ Time Frame: 22 days ]
    Bilirubin levels in the urine will be evaluated.

  37. The number of subjects with clinically significant changes in urine blood levels and relation to treatment will be assessed as part of a standard urinalysis panel (unless patient is anuric). [ Time Frame: 22 days ]
    Blood levels in the urine will be evaluated.

  38. The number of subjects with clinically significant changes in urine nitrite levels and relation to treatment will be assessed as part of a standard urinalysis panel (unless patient is anuric). [ Time Frame: 22 days ]
    Nitrite levels in the urine will be evaluated.

  39. The number of subjects with clinically significant changes in urine urobilinogen levels and relation to treatment will be assessed as part of a standard urinalysis panel (unless patient is anuric). [ Time Frame: 22 days ]
    Urobilinogen levels in the urine will be evaluated.

  40. The number of subjects with clinically significant changes in urine leukocyte esterase levels and relation to treatment will be assessed as part of a standard urinalysis panel (unless patient is anuric). [ Time Frame: 22 days ]
    Leukocyte esterase levels in the urine will be evaluated.


Secondary Outcome Measures :
  1. Hemodialysis efficiency as measured by frequency of clotting on the dialysis filters and circuit (pharmacodynamic outcome). [ Time Frame: 22 days ]
    Assessment of thrombus accumulation in the dialyzer cartridge measured by visual inspection.

  2. Hemodialysis efficiency as measured by blood urea nitrogen (BUN) levels (pharmacodynamic outcome). [ Time Frame: 22 days ]
    Assessment of BUN (mg/dL) before and after hemodialysis as well as KtV and urea reduction ratio (URR).

  3. Hemodialysis efficiency as measured by blood potassium levels (pharmacodynamic outcome). [ Time Frame: 22 days ]
    Assessment of plasma potassium (mEq/L) before and after hemodialysis.

  4. The effect of a single intravenous dose of E-WE thrombin on plasma activated protein C-Protein C Inhibitor complex (APC-PCI) levels as a surrogate for drug exposure. [ Time Frame: 22 days ]
    Plasma APC-PCI (ng/mL) levels will be determined by ELISA.

  5. The number of subjects that develop anti-drug antibodies will be summarized by frequency counts. [ Time Frame: 22 days ]
    Plasma anti-drug antibodies will be determined by ELISA.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. End Stage Renal Disease (ESRD) maintained on stable outpatient hemodialysis regimen, using an established (> 3 months) and normally functioning, regular flow, uninfected mature AV fistula (or AV graft) and skin consistent with standard chronic hemodialysis access injuries, and hemodialysis stability defined as Kt/V ≥ 1.2 within 3 months prior to screening at a healthcare center for > 3 months from screening.
  2. On hemodialysis regimen at least 3 times per week for a minimum of 3 hours per dialysis session, using a complication-free well maintained AV fistula (or AV graft), expected and plan to continue this throughout and for at least 3 months beyond the study.
  3. Is capable of understanding the written informed consent, provides signed and witnessed written informed consent and agrees to comply with protocol requirements and study related procedures.
  4. Willing to be confined to the clinical research unit for the duration of the study, able to comply with all study-related requirements, and able to adhere to study restrictions and visit schedules.
  5. Male or female, between 18 and 80 years of age (inclusive) at the time of screening.
  6. Body Mass Index (BMI) of ≥ 18 at the time of screening.
  7. Considered by the principle investigator (PI) to be clinically stable with respect to underlying ESRD, based on the medical evaluation that includes medical and surgical history, and a complete physical examination including vital sign measurements, electrocardiograms (ECGs), and clinical laboratory and coagulation test results at screening. Repeat assessments are permitted for any laboratory, coagulation, ECG, or vital sign parameter required for enrollment.
  8. Female patients must be of non-childbearing potential and must have undergone one of the following sterilization procedures at least 6 months prior to dosing:

    • hysteroscopic sterilization;
    • bilateral tubal ligation or bilateral salpingectomy;
    • hysterectomy;
    • bilateral oophorectomy;

    or be postmenopausal with amenorrhea for at least 1 year prior to dosing and follicle stimulating hormone (FSH) serum levels consistent with postmenopausal status as per PI or designee judgment.

  9. Male patients must either be sterile (vasectomy with history of a negative sperm count following the procedure); practice total abstinence from sexual intercourse as the preferred lifestyle (periodic abstinence is not acceptable); use a male condom with any sexual activity; or agree to use a birth control method considered to be appropriate by the Investigator from the time of dosing until 90 days after study drug administration. Male patients must agree not to donate sperm for a period of 90 days after study drug administration.

Exclusion Criteria:

  1. Documented history of acute vasoocclusive thrombotic event (acute coronary syndrome, stroke or transient ischemic attack, venous thromboembolic event), or vascular access fistula or AV graft failure in the past 3 months.
  2. With the exception of unfractionated heparin during HD that is allowed until study check-in, concomitant or prior use of anticoagulant/antiplatelet agents (e.g., low molecular weight heparins, warfarin, apixaban, bivalirudin, ticagrelor, edoxaban, dabigatran, rivaroxaban, clopidogrel, prasugrel, ticlopidine, eptifibatide, tirofiban, dipyridamole, diclofenac, and all other non steroidal antiinflammatory drugs) that may affect hemostasis for 2 weeks prior to check in on Day -8 and throughout the study.
  3. Any clinically significant (CS) concomitant disease or condition (including treatment for such conditions) that, in the opinion of the PI, could either interfere with the study drug, compromise interpretation of study data, or pose an unacceptable risk to the patient.
  4. Any other CS abnormalities in laboratory test results at screening or Day

    • 8 check-in that would, in the opinion of the PI, increase the patient's risk of participation, jeopardize complete participation in the study, or compromise interpretation of study data.
  5. Pregnant (positive pregnancy test) at screening or check-in on Day -8. If serum human chorionic gonadotropin (hCG) pregnancy test results are indeterminate, follow-up testing should be performed to determine eligibility. All female patients will not be pregnant and will have a negative pregnancy test at screening and check-in on Day -8, with the following exception: females receiving dialysis with an indeterminate pregnancy test result or persistently low hCG resulting in a false positive pregnancy test may be included in the study at the discretion of the PI. Postmenopausal patients with a result outside the postmenopausal range or an indeterminate pregnancy test will undergo additional testing with FSH to confirm postmenopausal status prior to study enrollment.
  6. Treatment with another investigational drug or participation in a device study within 30 days (or 5 half lives, whichever is longer) prior to check-in on Day -8.
  7. Acute illness that is considered by the PI to be CS within 2 weeks of check-in on Day 8.
  8. Surgery within the past 90 days prior to dosing which in the opinion of the PI or designee is clinically relevant.
  9. Currently have established underlying inherited or acquired symptomatic bleeding disorders and/or are at risk for excessive bleeding per PI judgment or current active bleeding (e.g., gastrointestinal, intracranial), aside from minor bleeding from the puncture site on the AV fistula or AV graft, which would be expected to occur during the dialysis procedure, with the following values:

    • Platelet count < 100,000 cells/mm3 (if < 100,000 cells/mm3 but > 75,000 cells/mm3, with permission of PI and medical monitor) at screening or check-in on Day -8.
    • INR > 1.4 at screening or check-in on Day -8
    • aPTT up to 1.2 x upper limit of normal (ULN) (if > 1.2 x ULN and up to < 1.5 x ULN, with permission of PI and medical monitor) at screening or check-in on Day -8
    • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 x ULN at screening or check-in on Day -8
    • Total bilirubin > 1.2 x ULN at screening or check-in on Day -8
    • Hemoglobin concentration < 10 g/dL at screening or check-in on Day

      • 8
  10. Seated blood pressure < 90/40 mmHg at screening and check-in on Day

    • 8.
  11. Exclusion criteria for ECG at screening and check-in on Day -8:

    Heart rate < 45 and > 110 bpm QTcF interval > 500 msec bpm = beats per minute; msec = milliseconds; QTcF = QT interval corrected using Fridericia's formula

    • Any significant arrhythmia or conduction abnormality, (including but not specific to atrioventricular block [2nd degree or higher], Wolff Parkinson White syndrome [unless curative radio ablation therapy]), which, in the opinion of the PI and Medical Monitor, could interfere with the safety for the individual patient.
    • Non-sustained or sustained ventricular tachycardia (> 2 consecutive ventricular ectopic beats at a rate of > 1.7/second).
  12. History of a CS allergy or a known sensitivity or idiosyncratic reaction to any compound known to be present in E-WE thrombin, its related compounds, or any compound listed as being present in the study formulation.
  13. Hypersensitivity to ß-lactam / penicillin derivatives.
  14. Participate in strenuous exercise from 72 hours prior to check-in on Day -8 and throughout the study.
  15. Positive test for drugs of abuse and/or positive alcohol test at screening or check in on Day 8 if not accounted for by a prescription medication. Patients with a positive test based on a prescribed medication may be enrolled.
  16. Positive test at screening for hepatitis B surface antigen (HBsAg) or human immunodeficiency virus (HIV). If a patient with ESRD has positive test results for hepatitis C virus (HCV) but liver function tests are otherwise not clinically significant, the patient may be included at the PI's discretion.
  17. Receiving blood purification therapy other than HD.
  18. Donation of blood or significant blood loss within 56 days prior to dosing.
  19. Plasma donation within 7 days prior to dosing.
  20. Presence of advanced malignant neoplasms of any organ or system that produces illness or symptoms that have been treated within 3 months with chemotherapy or whole body irradiation, or bone marrow irradiation, and may affect life expectancy in the following 6 months.
  21. Any other reason that would render the patient unsuitable for study enrollment at the discretion of the PI.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03963895


Contacts
Layout table for location contacts
Contact: Norah Verbout 5039640250 ext 5039640250 norah.verbout@aronorabio.com
Contact: Erik Tucker 5039640250 ext 5039640250 etucker@aronorabio.com

Locations
Layout table for location information
United States, Florida
Orlando Clinical Research Center Recruiting
Orlando, Florida, United States, 32809
Contact: Charles Johnson    407-472-0139      
Sponsors and Collaborators
Aronora, Inc.
Celerion

Layout table for additonal information
Responsible Party: Aronora, Inc.
ClinicalTrials.gov Identifier: NCT03963895     History of Changes
Other Study ID Numbers: EWE-19-02
First Posted: May 27, 2019    Key Record Dates
Last Update Posted: July 30, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Aronora, Inc.:
Hemodialysis
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Kidney Failure, Chronic
Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Urologic Diseases
Renal Insufficiency, Chronic
Renal Insufficiency
Thrombin
Hemostatics
Coagulants